These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39194339)

  • 1. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
    Padmapriyadarsini C; Oswal VS; Jain CD; Mariappan MV; Singla N; Kumar S; Daniel BD; Dave JD; Vadgama P; Ramraj B; Kant S; Bhatnagar AK; Shanmugam S; Paul D; Bharathi J; Palav M; Shah NV; Santhanakrishnan R; Dewan RK; Shekh N; Rathinam P; Sisara AB; Mankar SD; Bajpai J; Mittal U; Chauhan S; Kumar R; Parmar M; Mattoo SK; Jaju J;
    Clin Infect Dis; 2024 Dec; 79(6):1375-1385. PubMed ID: 39194339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.
    Goodall RL; Nunn AJ; Meredith SK; Bayissa A; Bhatnagar AK; Chiang CY; Conradie F; Gopalan N; Gurumurthy M; Kirenga B; Kiria N; Meressa D; Moodliar R; Ngubane N; Rassool M; Sanders K; Solanki R; Squire SB; Teferi M; Torrea G; Tsogt B; Tudor E; Van Deun A; Rusen ID;
    Lancet Respir Med; 2024 Dec; 12(12):975-987. PubMed ID: 39366400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
    Paton NI; Cousins C; Suresh C; Burhan E; Chew KL; Dalay VB; Lu Q; Kusmiati T; Balanag VM; Lee SL; Ruslami R; Pokharkar Y; Djaharuddin I; Sugiri JJR; Veto RS; Sekaggya-Wiltshire C; Avihingsanon A; Sarin R; Papineni P; Nunn AJ; Crook AM;
    N Engl J Med; 2023 Mar; 388(10):873-887. PubMed ID: 36808186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
    Song Y; Shu W; Pei Y; Du J; Wu G; Wang H; Mi F; Liu F; Ma L; Xie L; Kong Z; Wu X; Liu R; Chen H; Li H; Ge Q; Nie L; Lv Z; Huang X; Li M; Jiang M; Chen X; Cai Q; Chen W; Liu Y; Miao Y; Tang Y; Chen Y; Geng S; Zhou Q; Liu Y; Pang Y; Gao M
    BMC Med; 2024 Sep; 22(1):401. PubMed ID: 39300460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Korotych O; Achar J; Gurbanova E; Hovhannesyan A; Lomtadze N; Ciobanu A; Skrahina A; Dravniece G; Kuksa L; Rich M; Khachatryan N; Germanovych M; Kadyrov A; Terleieva I; Akhundova I; Adenov M; Durdyeva M; Kiria N; Parpieva N; Yatskevich N; Jumayev R; Nurov R; Diktanas S; Vilc V; Migliori GB; Yedilbayev A
    Lancet Infect Dis; 2024 Oct; 24(10):1151-1161. PubMed ID: 38880112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
    Bigelow KM; Tasneen R; Chang YS; Dooley KE; Nuermberger EL
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32690647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis.
    Martínez-Campreciós J; Aznar ML; Zacarias A; Terán R; Nindia A; Espinosa-Pereiro J; Aixut S; Ramos ME; Nicolau MJ; Sulleiro E; Tórtola MT; Sánchez-Montalvá A; Molina I
    J Infect; 2024 Dec; 89(6):106291. PubMed ID: 39426632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
    Haley CA; Schechter MC; Ashkin D; Peloquin CA; Peter Cegielski J; Andrino BB; Burgos M; Caloia LA; Chen L; Colon-Semidey A; DeSilva MB; Dhanireddy S; Dorman SE; Dworkin FF; Hammond-Epstein H; Easton AV; Gaensbauer JT; Ghassemieh B; Gomez ME; Horne D; Jasuja S; Jones BA; Kaplan LJ; Khan AE; Kracen E; Labuda S; Landers KM; Lardizabal AA; Lasley MT; Letzer DM; Lopes VK; Lubelchek RJ; Patricia Macias C; Mihalyov A; Misch EA; Murray JA; Narita M; Nilsen DM; Ninneman MJ; Ogawa L; Oladele A; Overman M; Ray SM; Ritger KA; Rowlinson MC; Sabuwala N; Schiller TM; Schwartz LE; Spitters C; Thomson DB; Tresgallo RR; Valois P; Goswami ND;
    Clin Infect Dis; 2023 Oct; 77(7):1053-1062. PubMed ID: 37249079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
    Dawson R; Diacon AH; De Jager V; Narunsky K; Moodley VM; Stinson KW; Liu Y; Zheng B; Hafkin J
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39612928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
    Lyons MA; Obregon-Henao A; Ramey ME; Bauman AA; Pauly S; Rossmassler K; Reid J; Karger B; Walter ND; Robertson GT
    Antimicrob Agents Chemother; 2024 May; 68(5):e0101023. PubMed ID: 38501805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
    Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
    Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.
    Lim AWY; Schneider L; Loy C
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD001747. PubMed ID: 39498781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation.
    Dias J; Tharmanathan P; Arundel C; Welch C; Wu Q; Leighton P; Armaou M; Corbacho B; Johnson N; James S; Cooke J; Bainbridge C; Craigen M; Warwick D; Brady S; Flett L; Jones J; Knowlson C; Watson M; Keding A; Hewitt C; Torgerson D
    Health Technol Assess; 2024 Dec; 28(78):1-262. PubMed ID: 39644138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Combined Bedaquiline and Delamanid Use among Patients with Multidrug-Resistant Tuberculosis in Beijing, China.
    Guo C; Nie L; Song Y; Liu R; Wu X; Shang Y; Zhang X; Pang Y; Gao M
    Biomed Environ Sci; 2024 Oct; 37(10):1195-1203. PubMed ID: 39622668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
    Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J; Sutton C; Šaulytė Trakymienė S; Tran H; Villarreal Martinez L; Wheeler AP; Windyga J; Young G; Thaung Zaw JJ; Eichler H
    Lancet Haematol; 2024 Dec; 11(12):e891-e904. PubMed ID: 39521008
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.